Other innovations
If your innovation doesn’t fit any of the active categories then this is the place to submit your innovation for feedback and the opportunity for wider adoption across the region.

Ideas (Long term conditions: a whole system, person-centred approach)

Innovation 'Elevator Pitch':
Teleswallowing enables poorly people to be seen more rapidly by specialists and improves staff productivity threefold
Overview of Innovation:
Teleswallowing is an approach using technology whereby a speech and language therapist can run a virtual clinic to triage, manage and review his/her patients with eating and drinking problems (dysphagia).  Teleswallowing Ltd staff train the carers within residential and care settings to be able to link remotely with speech therapists to provide rapid access to specialist skills to avoid unnecessary distress, avoidable deterioration and hospital admissions.  Speech and Language Therapy is a scarce resource and the waiting lists to see a specialist are long.  The use of Teleswallowing technology prevents vulnerable people suffering and can be used as an out of hours/weekend cover approach. 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Digital health / Innovation and adoption
Benefit to NHS:
I developed the approach at Blackpool where it is used; NWAHSN sponsored its development in Cheshire and West Hants CCG has commissioned the use in Southampton.  We have proven, through clinical trials supervised by Dr Liz Boaden from the University of Central Lancashire, that the approach increases staff productivity three fold and saves approximately £60 per assessment.  University College London used the approach in a workforce scoping project and found that 10.38 weeks of speech therapy time could be saved by using Teleswallowing.  Please see all evaluations on www.teleswallowing.com
Initial Review Rating
4.20 (2 ratings)
Benefit to WM population:
Many SLTs (speech and language therapists) are women working part time and below their level of training due to having child care or elderly parent responsibilities.  We would like to upscale our approach so that we not only offer training in the approach, but are able to deliver commissions for weekend/out of hours cover remotely, giving the opportunity for West Midland SLTs to work from home at hours best suited to their life and also help reduce the waiting times for sick people needing dysphagia assessments.  The SLTs would earn a better income, use their hard earned skills and be of benefit to the health system - by utilising a modern, digital approach.
Current and planned activity: 
The approach is used at Blackpool Teaching Hospitals, Cheshire and West Hampshire CCG.  I am bidding for a Women in Innovation award (Innovate UK) in order to develop the approach into an e-learning package, an app which then will be a digital clinic portal whereby SLTs will book in their availability to fulfil contracts remotely.  The SLTs will also be able to take advantage of the e-learning videos/second opinions/webinars which I intend to develop if I win the funding which goes with the Women in Innovation bid.
What is the intellectual property status of your innovation?:
Teleswallowing Ltd is a limited company and we have registered the name as ours.  The intellectual property is ours.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Veronica Southern 09/09/2018 - 15:59 Publish Login or Register to post comments
6
2
Votes
-99999
Innovation 'Elevator Pitch':
People living with dysphagia - swallowing difficulty - need drinks that flow slowly.
We are to help them make Slõ Drinks for all their healthcare needs.
Overview of Innovation:
For people with dysphagia, ordinary drinks like you and I have flow to fast for them to cope with.
As a result they choke when they drink, which can lead to aspiration pneumonia, malnutrition and readmission.

To prevent this they must make all their drinks flow slowly and at specific speeds. This is done by adding thickener using a scoop. However, it is very difficult to add the right amount with a scoop and make every drinks safe to swallow.

We have therefore taken all the drinks someone could need or want, calculated the amount required and put that in a sachet. Then sachet contents are simply mixed with the volume of liquid we specify to change drinks for hydration into Slõ Juice, Slõ Tea or Slõ Fizzy. Drinks for medication such as soluble laxatives into Slõ Solulax and drinks for relaxing with into Slõ Wine, Slõ Beer and Slõ Cider.

Oral Nutritional Supplements (ONS) are different.
 
Powdered and ready to drink ONS are difficult to impossible to thicken safely with starch and gum thickeners. Consequently, health care professionals prefer to reduce risks by prescribing Fresubin and Nutilis Complete pre-thickened ready-to-drink ONS.
 
They cost £2.20 each and the NHS spent £4,500,000 on them over the last year.
 
The innovation I want to introduce to your CCG's is an alternative which provide all the safety of a ready to drink ONS for the price of a powdered one. Called Slõ Milkshakes+ they are the 1st pre-thickened and powdered protein rich ONS on prescription.

Costing 84p each, they provide a saving per prescription of £ 80+ per month or £ 900+ per patient
per year. If Slõ Milkshakes+ were used during the same period they would have saved a massive
£ 2,800,000.

They also provide huge environmental savings. Slõ Milkshakes+ are presented in powder form in sachets. Not using single use plastic bottles, dramatically reduces the CO2 impact of manufacture, delivery and recycling. Our sachets can even be incinerated and used in energy recovery plan.
 
Just as importantly, Slõ Milkshakes+ are drinkable. Made with whole milk from the fridge, they taste fresh, do not taste too sweet or have a metallic aftertaste. Ultimately, that makes it easier gain compliance and maintain patient’s oral nutritional intake.
 
It’s for all these reasons they are being added to Formularies across the UK and why I want to introduce Slõ Milkshakes+ with the aim of introducing your CCG’s to
Slõ Milkshakes+.
 
There is additional useful information here: www.slodrinks.com/ons



 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Innovation and adoption / Person centred care
Benefit to NHS:
Slõ Milkshakes+ have been created to help reduce financial and environmental costs whilst improving patient outcomes - now and in the future.

Just focusing on costs - as previously stated, Slõ Milkshakes+ save £80.00+ per prescription. That may not seem like a huge amount, but the cumulative saving is huge.
 
From March 2017 to March 2018, the NHS spent £ 4,500,000 on Fresubin and Nutilis Pre-thickened ready to drink ONS. In comparison to spend on medications that is not a lot. However, spend on products for dysphagia is going to increase for two key reasons.
 
Firstly, healthcare professionals are not seeking to diagnose dysphagia. As recently as two months ago the Doctors dedicated website www.gponline.com made identifying Dysphagia a Red Flag topic.
The reason – they now recognise the impact dysphagia has on treating the primary condition.
 
If a patient is diagnosed with it every medication, drink and supplement has to be altered so it can be swallowed safely without inducing aspiration.
 
Secondly, it is a secondary symptom of 127 conditions including; Stroke, Alzheimer’s, Head and Neck Cancer and Motor Neurone Disease. These conditions present themselves typically in the elderly and dysphagia affects 10-12% of those over 50 – an increasingly large proportion of our population.   
 
We can therefore predict with certainty, if the spend on ready-to-drink Fresubin and Nutilis just remains the same the accumulative spend in 5 years will be £ 22,500,000.
 
By making Slõ Milkshakes+ a 1st line response for dysphagia now over the same period the cost of prescribing Slõ Milkshakes+ would only be £ 8,148,000, saving £ 14,352,000!

 
Initial Review Rating
4.40 (2 ratings)
Benefit to WM population:
Slõ Milkshakes+ make a positive impact to the health and wealth of the region through saving: saving patients from the risks of aspiration pneumonia, malnutrition and readmission; saving the CCG’s and healthcare professionals from unnecessary spend on expensive ONS for this patient group.
 
 
By providing a safe and reliable method to make safer to swallow ONS, Slõ Milkshakes+ reduce the risks of patients acquiring complications.
 
Patients will find it easy to consume the prescribed number of Slõ Milkshakes+ because they can actually drink them. They know they flow at the right speed and don’t need to worry about choking or embarrassing themselves in front of others – including their spouse.
 
When made Slõ Milkshakes+ look like ordinary milkshakes. No one can tell it flows slowly. It therefore doesn’t highlight their condition; gives them a feeling of inclusion.
 
Ultimately this makes for a better patient experience and improves compliance, which in turn saves them from the risks of malnutrition and re-admission.
 
Avoiding re-admission will save all the financial and patient costs associated with it, but and more importantly Slõ Milkshakes+ keep the costs of providing adequate nutrition in the Community to a minimum, saving CCG’s and healthcare professionals unnecessary spend on finances and time.
 
The financial savings are easy to quantify. Slõ Milkshakes+ will save £ 80+ per prescription every time a prescription is written for them instead of a ready to drink ONS.
 
Your CCG’s can quantify those savings by adding up the number of Fresubin and Nutilis Complete prescribed, multiplying by 84p (the Slõ Milkshake+ cost) and comparing the two.
 
Further savings are achieved by presenting Slõ Milkshakes+ in boxes of 7. A prescription can be written for just 7 sachets – a weeks’ supply – to see if a patient likes them. If they do, a larger prescription for one month’s supply can be written.
 
It’s also important to highlight the time saved, specifically time spent on implementation and training
in Nursing Home and Care Facilities where the majority of those with dysphagia reside.
 
These facilities typically have a high turnover of staff and many do not have English as a first language. As a direct result every Slõ Milkshake+ sachet features written and pictorial instructions to make sure they are always made correctly.
 
This makes training quick, easy and efficient, allowing health care professionals to focus on other important healthcare needs.
 
Current and planned activity: 
We are in constant contact with all divisions and levels of the NHS across the UK.
 
Our primary contacts have been healthcare professionals in Acute Hospitals, their colleagues in the Community and Doctors who have prescribed Slõ Milkshakes+.

During 2018 we have been focusing establishing relationships with CCG’s and their Medicines Management Team. We have been able to make contact via some Prescribing Support Dietitians but this has been difficult and slow.
 
This is why I have contacted all other ASHN's and yourselves - with a view to meeting your CCG’s and showing them how Slõ Milkshakes+ can help them and their patients.
What is the intellectual property status of your innovation?:
Our Competitors are giant Pharmacutical Companies and therefore a patent would be difficult to impossible to defend.
As a result I have had the Slõ Brand is trademarked here and in various Counties around the world.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Mathew Done 10/08/2018 - 10:17 Publish Login or Register to post comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Giving one drop of blood for analysis by SOMAscan informs me of my current health status, and helps my doc give me the right advice to reverse or prevent further disease development, or guide their treatment recommendations that will work first time!
Overview of Innovation:
The measurement of 5,000 blood proteins (a quarter of the human protein repertoire) is now possible on a reproducible and industrial scale in clinically-accredited central lab settings. Prior analysis of hundreds of thousands of study subjects' and patient blood samples, whose basic & physiological measurements, life style and clinical histories have been collated, has been used to create a suite of health status defining algorithms that define risk of disease event occuring over 1-5 year time horizons, rates of development, and likelihood of response to alternative intervention that are available.  Whereas rudimentary 'disease risk' insights such as Framingham cardiovascular diasease (CVD) risk scores and QRISK2 are used in public health, primary care and specialist acute care settings to augment disease prevention or guide optimal treatment choices, it is now possible to expand this range of probablistic medicine insights.  Expanding the repertoire beyond CVD to include pre-diabetes conversion to full diabetes or development of complications (amputations, kidney failure, blindness) that lead to costly or catastrophic outcomes, is a starting point.  However, diseases such as non-alcoholic fatty liver disease and steatohepatitis, which leads to liver cancer & failure is another silent killer whose development can be revealed just by applying a different status-prognosis algorithm to protein measurements derived from the same blood sample.  Chronic disease management and care accounts for ~70% of healthcare costs with diabetes alone consuming 10% of the NHS' entire budget and so these are worthy of attention for  prevention, early disease interception (at a reversible stage), or optimising existing care paths that maximise available resources to deliver disease management interventions.  Our primary focus is to prolong and improve population wellbeing such that patient treatment outcomes leads to broad adoption.  However, whereas traditional diagnoses rely heavily on clinical symptoms, SomaLogic's AI-derived algorithms consider the molecular underpinnings of disease.  Clinically-defined diseases are treated in standardised ways which doesn't always work.  Identifying patients with treatment-refractory disease could help target those into research programmes including clinical trials for novel regimens or pharmacological agents.  A secondary output of routine adoption could be creation of an accelerated trial recruitment resource to attract pharma partners.
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Healthcheck, although ultimately funded by Public Health England, commissioned by City Councils and delivered through contracted CCGs/GPs, is of questionable value.  A battery of tests whose results are combined with additional clinical parameters and a consultation with a GP or practice nurse, is designed to pre-empt intervention in patients with rising risk for cardiovascular disease or identified as having 'frank' disease.  The net contribution based on opportunity savings delivered to the NHS and the cost of delivering the HealthCheck programme is close to zero.  The repertoire of diseases whose status can be tested for, could be expanded to include multiple silent diseases, as well as provision of range of physiological status-related insights that could complement the patient review process.  For example, patients at risk of developing frank diabetes could be managed more objectively and successfully.  A reduction by 1% of patients converting to full diabetes could equate to £100 million/year by their avoidance of costly complications such as stroke, amputations, kidney failure and blindness.  Avoidance of liver failure associated with liver fibrosis, could contribute further significant opportunity savings: Coupling life style (e.g. dietary education or excercise on prescription) or emerging pharmacological interventions with conveniently measured disease status insights will be required.  However, rather than creating increased burden on NHS resources, provision of clinically validated insights but could also create opportunities for third party organisations beyond the NHS in offering relevant health-maintaining or disease-reversing solutions.
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
In a county in which 29% of the population is clinically obese there is a higher risk compared to the majority of the UK population, for diabetes and also fatty liver disease-related complications.  Treatment costs for the latter alone costs the NHS (England) around £1billion/year.  Providing disease risk insights to citizens and their health practictioners, particuarly if the information is objective and made actionable, could be used to support increased health literacy, increase patient activation (motivation), and support the best choice and resource-optimal delivery of advice and clinical interventions.  Ultimately, compliance with such advice and insights will improve the healh of the local population, reduce the burden of dependancy on long-term chronic disease care, and perhaps even result in development of a health-focused preventive health solution provider market.
Current and planned activity: 
SomaLogic has submitted plans for implementation of diabetes risk and complication development predicting algorithms in the routine primary care setting in Leeds (one CCG and 3 GPs). The objective is to use the more objective patient profiling (identified through hypertention clinics) to promote deeper patient enagement measured through increased patient uptake of commissioned nutritional education programmes and/or gym by prescription.  Logistics around blood collection, processing, analysis and data delivery and presentation will be evaluated and optimised, after whcih there is scope to expand this initiative to a wider geographical region.  However, there is scope to evaluate the utility of additional disease status (risk), and prognostication algorithms within the different clinical settings and associated clinical workflows, in neighbouring geographies.
What is the intellectual property status of your innovation?:
SOMAscan is a patented proprietary protein measurement technology.  Algorithms developed using artifical intelligence to mine for associations between patient characteristics, lifestyle histories, clinical interventions and decades of clinical follow-up/outcome data (2 million years) that correlate with patterns for 5,000 protein measurements (mined from 2 billion protein data points), provides a highly defensible starting position.
Return on Investment (£ Value): 
Very low
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
2
Read more
Hide details
Anthony John Bartlett 11/07/2018 - 15:11 Publish 2 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
This project uses art to inspire and inform, targeting geographical areas of social disadvantage where breastfeeding rates are low/ mothers may not have access to current research and may be unduly influenced by cultural barriers to breastfeeding.
Overview of Innovation:
Funded by ACE from 2017-18, the series of twenty-three photographic portraits of mothers breastfeeding by Lisa Creagh (Artist Practitioner) was animated into a film and exhibition-ready prints in January 2018. From January – May ‘Holding Time’ was shown at Fabrica Gallery, ONCA Gallery and Royal Brompton Hospital in London, in print, video and installation formats, accompanied by talks and workshops. ONCA featured a Breastfeeding Hub where comfortable seating encouraged mothers to stay longer and talk with other mothers. 
 
A dedicated website (www.the-parlour.org), was set up to broadcast interviews using Lisa Creagh’s YouTube channel. Here interviews by Lisa Creagh and Lucila Newell with participating mothers were posted as 5minute Podcasts. A Facebook promotion and postcard campaign drew visitors to the website, where a BLOG written by Sociologist Lucila Newell explored issues surrounding the cultural barriers to breastfeeding and an events page directed them to exhibitions and workshops/talks.  
 
Findings:
  1. Responses from audience at exhibitions was more mixed in gender and age than anticipated
  2. Workshops and talks were attended by more academic, medical and health researchers/practitioners than expected
  3. Online sharing of ‘Holding Time’ slideshow brought a large proportion of the audience to Podcasts 
  4. ‘The Parlour’ was not needed as a separate brand identity for the website: numbers of direct visitors were less significant than online sharing and YouTube recommendations. 
  5. The Breastfeeding Hub resulted in longer visits to exhibition
  6. Interviews/talks/workshops revealed structural barriers within health practice.
 
Figures (Jan-May 2018) 
 
Exhibitions x 10 days/ 435 visitors
Website: 1,000 users/ +67%
Talks x 2: 70 attendees
Facebook fans 303 posts/+91 fans/ +695 engagement
Instagram: +87 posts/+346 followers/ +1.4k engagement 
Twitter: 155 Tweets/+55 Followers/+25 engagements 
YouTube Analytics: 8,907 Views/ +6,710/60 Likes/+63 Subscribers
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Innovation and adoption / Person centred care
Benefit to NHS:
There is a wide disparity between the emphasis on breastfeeding in culture and the support for mothers attempting to breastfeed for the first time. There are approximately 700,000 newborn babies in the UK each year. Of these, a high proportion will be to new mothers with no experience or understanding of breastfeeding. Much funding for Health Visitor run baby groups and drop-ins throughout the country have been cut in the past two years due to budget constraints, leading to increasing social isolation of new mothers. Young mothers in particular may not have ever encountered another breastfeeding mother, given that the last generation was largely encouraged to bottle-feed. 

Holding Time is a project designed to address inequality and lack of opportunity. We know from a huge body of evidence that breastfed babies have better short and long term physical and emotional health outcomes.[1]But drop out rates in breastfeeding are still perilously high. Currently young women from disadvantaged backgrounds have breastfeeding rates of less than 29%[2]. But until cultural attitudes towards breastfeeding change, it is unlikely that this will be improved. 
 
One of the greatest challenges new mothers face is overcoming the dominant negative attitude towards breastfeeding in public[3]. The Infant Feeding Survey 2010 shows that In Brighton, breastfeeding rates are higher than the national average, but these statistics hide inequalities. 

The nature of this work is discursive,opening dialogues around breastfeeding between not only women, but also genders and generations where arguably there can be wide disparities in opinion. 

Using social media, a local postcard campaign to GPs, and a YouTube channel, the project uses the exhibition in a local community space as an opportunity to engage and invite the public to engage in multiple ways.
 
[1]Department of Health. Breastfeeding and the NHS Priorities and Planning Framework 2003-2007 (modified February 2007). London: Department of Health. www.dh.gov.uk/  
[2]https://www.jfhc.co.uk/Who_wants_to_eat_in_a_toilet_20947.aspx: “The prevalence of initiation of breast-feeding varies between neighbourhoods from 28% to 80.6%.”
[3]45% of mothers reported that they felt uncomfortable breastfeeding in front of other people, and this was most acute in public places (43%) http://www.hscic.gov.uk/catalogue/PUB08694/Infant-Feeding-Survey-2010-Consolidated-Report.pdf
Benefit to WM population:
Looking at the Public Health England Statistical findings of 2017/18 Quarter 3: the latest data on breastfeeding prevalence at 6-8 weeks after birth, areas such as Stoke on Trent, Sandwell and Nottinghamshire have particularly low rates of breastfeeding (31.8%, 37.2% and 39.5% respectively) for example but again these statistics represent take up, which would drop considerably within a couple of months. Given that the WHO has recently defended its position of the benefits of breastfeeding for at least two years, the challenge is to inspire this minority of mothers who do take up breastfeeding to continue for longer and to inspire more mothers to try, particularly young women who seem to struggle with the public face of breastfeeding. 
Current and planned activity: 
Next Stage:
 
  • Stimulate and curate conversations around breastfeeding to the public 
  • Dr Debra Bick (Expert)/Lisa Creagh to approach medical and academic researchers in the field of breastfeeding for content and collaboration
  • Podcast interviews with medical researchers, Paediatricians, midwives and heath practitioners to inform and integrate research with opinion, capitalising on the wide reach of YouTube platform. 
  • BLOG to comprise of guest posts by medical researchers focusing on issues raised by women in workshops and interviews e.g. the struggle to feed in the early stages, the establishment of lactation, post partum care, expressing, breastfeeding in public, etc
  • Tour of Holding Time to locations across the UK with low breastfeeding rates, including Breastfeeding Hubs where possible/appropriate
  • Facebook/Instagram channels to promote the exhibitions and web content above 
  • Accessibility expanded through transcripts/closed caption subtitles 
What is the intellectual property status of your innovation?:
Copyright of all images is held by Lead Artist Lisa Creagh
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Read more
Hide details
Lisa Creagh 15/06/2018 - 15:13 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
We're developing an Autonomous Patient Observation System (APOS) which will automate patient observation in any environment.
Overview of Innovation:
We're a start-up creating an Autonomous Patient Observation System (APOS) which collects user data from facial expressions, physical activities, gait analysis, user habbits, agression and agitation, and so on. We're looking to provide a fully autonomous device which can gather all that data and generate reports, insights, classifications and statistical analysis.
The APOS device is the size of a can of beer, and is extremely easy to use; just register the patient, and let it work for as long as you need to. It does not use cameras, but only lazer depth sensors, and the final product will be low-cost. The APOS device aims to provide impartial, aggregated meta-data and insights, in order to make assessments and evaluations simpler, faster and more accurate.
We're focusing on a Dementia Observation System, and are also interested in frailty indexing. We will be releasing the beta product end of September, and if you would like to test one for free, please contact us.

You may find more information on our website: https://www.mechion.com
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Digital health / Innovation and adoption
Benefit to NHS:
  • cost reduction because less workforce is needed to monitor and observe patients
  • time reduction because the task of observing and monitoring becomes automated
  • better quality of service: assessments become more accurate and decions more informed due to big data acquisition
  • product could potentially be used in homes, thereby reducing the need of placing patients in facilities
  • earlier diagnosis could be possible, remote diagnosistics and low-cost observation regardless of facilities
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
  • better quality of service received, since more data is collected on a 24/7 basis
  • reduction of costs will allow care-workers and nurses to focus on more important tasks, thereby helping the patients more
  • better and earlier diagnostics can potentially help patients sooner
  • patients could avoid hospitalisation, and be monitored from home
Current and planned activity: 
We are currently engaging international organisations (research clinics and Universities) but are looking for early adopters in the Midlands. We have interviewed and identified key problems and issues we can solve with machine learning and AI and are now moving into prototyping. We should have a beta product ready for testing end of September.
What is the intellectual property status of your innovation?:
Software and Hardware
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
4
Read more
Hide details
Alexandros Gkiokas 16/05/2018 - 12:50 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Our web based visualisations of NHS datasets is disrupting the analytics market. It allows systems to understand cause and effect within their health economies and test hypothesis in real time by interacting with the data through drop down menus
Overview of Innovation:
Our vision is to give every NHS system leader in England a clear picture of the end to end journey for the populations they serve. At the same time we aim to save the NHS £millions by disrupting the market for low level analytics!
The challenge currently faced by all healthcare leaders is a lack of insight and meaningful, consistently-reported analysis regarding the position and performance of the healthcare system. This lack of insight hampers the efficacy of the strategic and operational planning process and the scope and effectiveness of monitoring and oversight.
This challenge sits in the context of masses of existing publicly available healthcare data. Data that’s time consuming for providers to prepare but underutilised due to its format, shape and local capacity and capability.
Our vision is to make VUIT.ONLINE, our information and insight portal, available across the entire NHS in England. The tools we’ve developed allow users to interrogate data across an provider, CCG, ST or ICS quickly and efficiently in a way which informs decision making and allows the impact of interventions to be validated using existing national datasets.
VUIT.ONLINE re-configures, combines and visualises NHS and other national datasets in a way that allows them to be used to understand system and provider performance and demand in context.
Our front-end combines different datasets to create insights not available from any one alone, for example combining DTOC data with hospital bed-base to understand the effective scale of the DTOC issue, or comparing RTT data with consultant workforce to contextualise waiting list trends.
By doing this we can support system leaders to gain a deep understanding of cause and effect related to key strategic issues within their ICSs and model the impact of decisions they may wish to make to address those issues.
All this is achieved with data which is consistent across all providers, layered from multiple data sources and, most importantly is instantly available, at the national, regional and place based level for comparison and analysis through an online portal.
The impact of VUIT.ONLINE is not just the creation and availability of new insights from data, but the speed at which it can be manipulated to test hypotheses.The financial viability of VUIT.ONLINE comes from its ability to deliver this with an absolute lack of in-house or procured analytical or BI resource in the form of consulting and CSU costs which currently run into many millions.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Clinical trials and evidence / Innovation and adoption / Person centred care
Benefit to NHS:
VUIT.ONLINE re-configures, combines and visualises NHS and other national datasets in a way that allows them to be used to understand system and provider performance and demand in context.
We do this in a pre-packaged but evolving, continuously-updated front-end combining different datasets to create insights not available from any one alone, for example combining DTOC data with hospital bed-base to understand the effective scale of the DTOC issue, or comparing RTT data with consultant workforce to contextualise waiting list trends.
By doing this we can support system leaders to gain a deep understanding of cause and effect related to key strategic issues within their ICSs and model the impact of decisions they may wish to make to address those issues.
All this is achieved with data which is consistent across all providers, layered from multiple data sources and, most importantly is instantly available, at the national, regional and place based level for comparison and analysis through a scalable online portal.
The impact of VUIT.ONLINE is not just the creation and availability of new insights from data, but the speed at which it can be manipulated to test hypotheses at system level from the system’s own, current data within existing national datasets.
The financial viability of VUIT.ONLINE comes from its ability to deliver this with an absolute lack of in-house or procured analytical or BI resource. A fundamental success factor for the implementation of this innovation is a reduction in the cost of low-level analytical support to the NHS in the form of consulting and CSU costs which currently run into many millions.
Initial Review Rating
3.00 (2 ratings)
Benefit to WM population:
By giving system leaders the tools they require to effectively build end to end, whole system pathways and commission them outcomes will improve for the people of the West Midlands. However the way in which our innovation VUIT.Online is configured this benefit is freely available to all health economies in England
Current and planned activity: 
We are currently mid way theought the second wave of Test Bed applications where we are both an innovator and a defined test bed partner with a West Midlands CCG
What is the intellectual property status of your innovation?:
VUIT. Online and it's intellectual property is owned by its co-founders. It is built on licenced propriatry software and uses national data sets which exist in the public domain
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
VUIT. Online uses national data sets, propriatery analytcal software and globally recognised web developer frameworks (wordpress). As such it is scaleable across the entire NHS in England immediately
Measures:
Measurable outcomes:
-reduction in spend on low level analytics in the NHS in england
-reduction in patient pathway costs as health economies understand whole system costs more effectively and plan ICS's on this basis
-Improved ability to scale innovation in healthcare by giving innovators access to data which will support, clarify and stratify the way in which they develop and take their products to market
Adoption target:
We aim to make the resource available to all NHS managers in England through sharing examples of best practice around the use of VUIT.Online
Read more
Hide details
Adam Townsend 25/04/2018 - 14:31 Detailed Submission Login or Register to post comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Raiing Medical manufactures non-invasive Connected Vital Signs Monitoring for essential clinical decision support, healthcare cost savings, and better quality of care through big-data analysis and AI technology for inpatients and outpatients.
Overview of Innovation:
Currently, the majority of patients in hospital have measurements of vital signs taken manually at 2 to 4 hour intervals, which means some irregular events on the patient may go undetected for hours, this will lead to serious consequences including additional treatment, re-admittance to intensive care units, or even death. On the other hand, the lack of qualified data after patients leave the hospital also increases the difficulties for doctors to identify a patients situation at home. 
 
Raiing Medical believes wearable and mobile technology will change this situation, therefore Raiing is pleased to announce that Raiing MPCMS solution is now available. Raiing MPCMS is a continuous multi-parameter central monitoring system with smart sensor interface and transceiver, which arms to better monitor patients’ vital signs and eventually improve patients’ safety. With the support of a wearable medical sensor and unique Raiing VitalCube, nurses/care givers could receive constant ECG, TEMP, Heart Rate, Respiratory Rate, Sp02 signals from multiple inpatients and alarm for irregular readings simultaneously into a central monitoring station or hospital IT system.  
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Digital health / Person centred care
Benefit to NHS:
Raiing Wearable Vital Signs Monitors will cut down dramatically on Caregivers intervention, provide essential patient data for Hospital use, Home Caregivers use and Doctors Surgeries.  The net result is an increase in patient's quality of life,  significant reduction in readmissions to hospital and considerable savings to the NHS and beyond.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
Our Wearable Monitors will allow for vital signs testing on the operating table, ICU, recovery in Hospital and uninterrupted monitoring in the home. Caregivers will pick up on fluctuations and administer assistance immediately saving readmissions to hospital or doctor intervention.
Current and planned activity: 
Our products are widely in use in China and the US.  We are now looking to introduce our products into the UK and Europe and are taking part in the Nightingale, Horizon 2000 project but have not yet had the chance to work with the UK NHS.
What is the intellectual property status of your innovation?:
Wholly OIwned by Raiing Medical Company, Beijing, China.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
John Sweeney 30/03/2018 - 12:29 Sign Posted Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Consultant Connect enables a GP to dial a single number to immediately reach an appropriate specialist.  Immediate Advice and Guidance is better for patients, clinicians & NHS. It is currently used in Elective, Urgent & Mental Health care settings.
Overview of Innovation:
Consultant Connect www.consultantconnect.org.uk is a simple CCG funded telecoms system that provides GPs with immediate access to telephone-based specialty mental health advice and guidance. By talking to a specialist, often whilst the patient is still in the surgery, the GP is better able to provide the right care first time to the patient, often avoiding an unnecessary referral or admission.  The specialist is based within a nearby NHS Trust Hospital.
 
GP calls connect directly, via a standard rate number, to teams of local specialists via their mobile phones with each specialist getting c 20 seconds to answer a call before it automatically forwards on to the next specialist. By connecting to teams of specialists, rather than to individuals, the connection rates are high.  The order in which specialists receive calls is based on a Rota of specialist availability that has been provided by the team. This rota can be either managed by us or by the team itself through an online portal.  The team of specialists are based in the local NHS Trusts.
 
Once connected, calls are recorded as highly encrypted, information-governed digital files which provide a medico-legal record which is available to the relevant GP practice and specialist team.  At the end of the call GPs are asked to stay on the line for a few seconds to rank the outcome – this gives the CCG a broad view as to the effectiveness of the system and their investment in it. Specialists are also asked to rank the outcome via text message as a back-up.
 
This service is in operation nationally across many specialties in physical and mental health.

In what instances should/can Consultant Connect be used?
The way in which this system is used is ultimately determined by the CCGs, Trust/Specialists and GP practices collectively, but it is generally accepted that calls will be made for patient-specific advice.
 
Within mental health we can connect GPs to the most appropriate mental health clinical professional (e.g. Psychiatrist, Psychologist, Cognitive Behavioural Therapist) to discuss issues such as:
  • Whether a referral is needed
  • Medication management/prescribing questions
  • Access to crisis support
We offer our service to best meet local needs between service users, GPs and Mental Health Trusts. 
 
We can tailor by service, specialty or pathway.
The speed of connection is such that the GP’s can (at their discretion) call whilst a patient is still with them.

Consultant Connect Service
https://www.youtube.com/watch?v=QWmNUubMCAE
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Why Trusts and CCGs work with us
  • Better patient experience – speeds up the care pathway, avoidance of unnecessary visits and contact with secondary care services, reductions in follow-up visits to GP Practices
  • Better GP experience – more patient episodes conclude with no follow-up work, case based learning, reconnecting with specialists
  • Better specialist experience – reduction in inappropriate referrals to secondary care services, reduction in the number of written requests for advice that require responses, reconnecting with GPs
  • Better for the mental health trust and CCG – full tracking of Advice & Guidance activity, greater ‘whole system’ efficiency, with savings available to support other hospital and community initiatives

How we perform
  • In Physical Health, across all elective care specialties, 66% of calls to Consultant Connect result in the patient avoiding a trip to hospital (referral or admission)
     
  • In Physical Health, across all of urgent care specialties, 27% of calls avoid a hospital trip that day (attendance or admission) and a further 36% of from A&E
     
  • In Mental Health, 39% of calls to our Mental Health Advice & Guidance line avoided a referral
 
What a Consultant Connect call has meant to …
… GPs
“The call enabled me to deal with some abnormal results in an efficient manner – which tests to request and what to do with the results. Saved a referral.”

… Consultants
“I took a call regarding a patient with syncope and ataxia. I avoided an unnecessary admission and got the lady seen urgently in an outpatient clinic.”

… Commissioners
“Consultant Connect is our only QIPP scheme that is over delivering against its YTD QIPP target. I’m genuinely struggling to know how to deal with all this positivity. It’s very unusual in my line of work. Great news.”
 
Testimonials:
https://www.youtube.com/watch?v=vEu7QDT4PzI
 
Initial Review Rating
4.80 (2 ratings)
Benefit to WM population:
Nearly 2,000 patients were spared an avoidable visit to hospital in the West Midlands by GPs who used Consultant Connect to contact specialists for immediate advice.
 
Doctors in the West Midlands turned to Consultant Connect, which allows them to speak to a specialist, often with the patient still in the room and can save them waiting days for a response or being sent to hospital for further checks.
 
Around 1,850 patients were spared going to Sandwell Hospital as well as Heartland and Good Hope Hospitals in Birmingham.
 
The service covers cardiology, diabetes and endocrinology, gastroenterology, gynaecology, general surgery, haematology, paediatrics, renal medicine, urology and respiratory medicine.
 
Since the phone line launched, GPs from 100 surgeries across Walsall, Sandwell and Solihull have made nearly 2,500 calls to specialists to get expert advice on the best care for their patients.
 
Consultant Connect estimates that West Midlands GPs and consultants have saved the NHS £570,000 by ensuring patients get the right treatment from the beginning.
 
When local GPs used Consultant Connect, around 50 per cent of their patients avoided the inconvenience of a trip to hospital.
 
Ref: Pharmacy Choice, 9 June, 2017
https://www.pharmacychoice.com/news/article.cfm?Article_ID=1832970
In one West Midlands CCG, the number of outpatient referrals dropped by 6 per cent over a three-month period.   This was Solihull CCG into HEFT (Heart of England Foundation Trust). 
https://www.consultantconnect.org.uk/breaking-news-ccg-establishes-consultant-connect-responsible-for-6-dip-in-referrals

We are currently working with the following CCGs in the West Midlands AHSN area:
 
Solihull CCG, Coventry and Rugby CCG, South Warwickshire CCG, North Warwickshire CCG, Worcestershire (South Worcestershire CCG, Redditch and Bromsgrove CCG and Wyre Forest CCG).  We are also working with the GP Federation Modality Partners in Sandwell.
 
We are working with the following Trusts:
  • HEFT - Heart of England NHS FT
  • SWFT - South Warwickshire NHS FT
  • UHCW - University Hospitals Coventry and Warwickshire NHS Trust
  • WAHT - Worcester Acute Hospitals NHS Trust
  • Sandwell and West Birmingham Hospitals NHS Trust - SWBH
  • George Eliot Hospital (GEH)
Current and planned activity: 
Current activity:
We are delivering Consultant Connect with over 45 CCGs across the UK, covering more than 12.8 million patients and over 1,700 GP practices.  To date we have handled 98,000 calls.

Planned/Required activity:
We would like to further roll out Consultant Connect to willing GPs and Trusts.  We would also appreciate any assistance in undertaking a formal return on investment review of our service to show very clear and robust data that we save money, and quickly.
 
What is the intellectual property status of your innovation?:
Consultant Connect Ltd own the telecoms system software and BI data reporting.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Jenny Welling-Palmer 15/02/2018 - 13:38 Publish 1 comment
6
1
Votes
-99999
Innovation 'Elevator Pitch':
NATROX® Oxygen Wound Therapy is a medical device designed to heal complex non-healing wounds to improve healing outcomes and quality of life, optimise clinical and economic resources, and reduce diabetic foot related amputation rates.
Overview of Innovation:
NATROX® Oxygen Wound Therapy is a portable, lightweight and easy to use patient-friendly device, designed to topically deliver continuous pure humidified oxygen to the wound bed. The device was developed in order to help improve healing outcomes in wounds which traditionally remain static due to wound hypoxia (oxygen starvation), a common symptom of diabetic and vascular issues.

The NATROX® system is comprised of an Oxygen Generator, 2 rechargeable batteries and a single-use disposable Oxygen Delivery System.  The therapy is designed to be used 24/7 and as an adjunct to standard of care, such as absorbent wound dressings, with an average therapy length of 12 weeks. The product is supported by a growing portfolio of clinical evidence, including RCT-level data, which has demonstrated a significant increase in the healing rates of complex and non-healing wounds, compared to standard of care alone (90% healing with NATROX®  vs 30% for standard of care).
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Innovation and adoption / Person centred care
Benefit to NHS:
It has been shown that over £5.3bn is spent by the NHS each year on the management of 2.2m wounds. The management of non-healing wounds accounts for a significant amount of NHS resources (approx. £3.1bn per year) and is increasing due to an ageing population and higher rates of diabetes and diabetic foot ulceration.  NATROX® therapy is designed to positively impact healing rates and thereby optimise both clinical and economic resources used on non-healing wounds, in turn helping clinicians and financial decision-makers to access and treat a greater number of patients.

Furthermore, it is well documented that patient quality of life is negatively impacted by having a wound, and especially a non-healing wound, with increases in social isolation and depression across this patient population. NATROX® therapy focuses on healing wounds which are unable to heal with standard treatments alone, as these treatments are unable to address the underlying causes of non-healing wounds, such as oxygen starvation (hypoxia). The therapy system therefore focuses on providing pure humidified oxygen to hypoxic wounds, whilst being comfortable, quiet, lightweight and easy-to-use for the patient, allowing normal mobility without any negative impact from the device.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Increases in diabetes rates across the UK has in turn led to an increase in prevalence rates for diabetic foot disease and associated ulcers.  Furthermore, latest health economic evidence (e.g. Guest et al 2015 & 2017) has shown that non-healing wounds account for approximnately 57% of wounds at any time are deemed non-healing, which has a direct impact clinically, financially and to the patient experience.  Both minor and major amputation rates are increasing as a result due to the complexity of many diabetic foot ulcers, which has a significant impact on the health and wellbeing of these patients, with increased patient mortality following amputations of around 50% within 2 years.

Like many areas, the West Midlands is experiencing increased amputation rates, as a result of rising diabetes and diabetic foot ulcer prevalence.  This has a significant impact on the local health economy in the West Midlands area, especially in higher population bases such as city areas and surrounds.  Therefore, the adoption of NATROX® therapy across the West Midlands area could have a significant effect on helping to reduce non-healing levels within the diabetic foot ulcer population, and therefore positively impact the well documented clinical and economic cost that the burden of non-healing wounds brings with it.  

A resulting increased resource utilisation would allow a wider focus on the growing population of diabetic foot ulcer patients, improving clinical and economic output across local vascular, podiatry and wound management services.   
Current and planned activity: 
Inotec AMD is currently engaged with a variety of clinicians and decision-makers across the UK.  There are a number of local product evaluations active or soon to start, which will aim to demonstrate product afficacy in order to facilitate adoption of the technology locally and nationally.  in addition, a large NHS funded UK-based RCT is underway, which is due to report later in 2018.

Furthermore, the product is being reviewed both clinically and evidentially on a national level in both Scotland and Wales, where we are about to start a national clinical evaluation in Wales across both Welsh Podiatry and Tissue Viability networks, whilst in Scotland NATROX® therapy is being formally assessed by Health Improvement Scotland and the Scottish Health Technologies Group, in order to gain an official recommendation. 
What is the intellectual property status of your innovation?:
The intellectual property surrounding NATROX® therapy is owned by Inotec AMD Ltd.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
NATROX® Oxygen Wound Therapy is not yet adopted at scale within the UK, but is undergoing product evaluations with a view to contract listings and wider adoption.  A programme of marketing and events is planned to support the wider awareness and adoption of the technology.
Measures:
Further clinical efficacy demonstrated through local and national product evaluations, health efficiency data supported by the NATROX® Health Efficiency Model utilising local clinical data and outcomes, patient quality of life data from local and national product evaluations, and usability info from clinical usage.
Adoption target:
Availability of NATROX® Oxygen Wound Therapy on podiatry, vascular and tissue viability product formularies and listings in hospitals across WM region, for use on all clinically relevant non-healing and complex wounds. 
Read more
Hide details
Nick Howard 12/02/2018 - 18:23 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Digital Transfer bag for essential clinical patient information such as medical, falls and frailty information, diet/nutrition/hydration etc. To improve patient safety and provide important information to HCP's for patients conveyed.
Overview of Innovation:
Creation of a Digital Transfer bag for essential clinical patient information such as medical information, falls and frailty information, diet/nutrition/hydration etc. To improve patient safety and provide important information to Health Care Professionals for patients conveyed to Emergency Departments, hospital appointments or occupational therapy services. The app can also incorporate additional elements that will help to tailor their care such as an electronic falls risk assessment (eFRAT), simple initial questionnaires i.e. recent coughs and colds, general health, mental health, stability checks. Integration of Point of Care testing such as UTI testing for symptomatic patients. Results can be emailed to GP/ night nursing services for treatment prescription if required. Quick identification and treatment can improve patient experience and reduce falls risk associated with UTIs.
Stage of Development:
Ideas stage - Early concept and ideas stage
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Frail older people living in care homes are amongst the most vulnerable in our society.  Often simple referrals for outpatient clinics are aborted due to lack of sufficient information available and availability of knowledgable staff to accompany the patient.  Calls to paramedics result in conveyances for the same reason.
Within a care home when someone is conveyed to hospital they must be accompanied by a member of staff, this could be any one who is available, and they may not have a lot, if any, medical knowledge or knowledge of the persons previous health. Using an app would mean anyone would be able to travel to hospital with the patient as they would have all the information they would require on admission.
Currently personal and clinical information and standardised paperwork is being sent along with the patient in the ambulance. This opens up the possibility of sensitive data being lost, or not passed on to the care team who need it. The app would store encrypted data within the N3 network. Could utilise DM+D (Dictionary of medicines and devices) to reduce input error for medication information.
Ideally this could be operated in a phased approach with basic services initially and others added on in a second phase.
Care homes provide a vital service within the national health and care system, however due to insurance requirements many have become increasingly risk-adverse, insisting that the slightest stumble, confusion or change in a patient be medically reviewed.  With falls alone this results in calls to ambulance services that often result in unnecessary conveyance because the information is not routinely available.  Clinical, paramedic and patient time is wasted due to repeated appointments and attends due to insufficient information available at the point of incident.
 
Benefit to WM population:
Improved, faster treatment for illnesses, remote monitoring by qualified staff reducing need for appointments and long waiting times.  Nominated professionals and individuals can hold virtual consultations using shared information.
Current and planned activity: 
Early engagement and development has been discussed as part of an existing AHSN project in the East Midlands, but this area of work is not part of that project, and has been identified as an area of innovation and improvement.
A digital platform is already available and can quickly be tailored to deliver many of the requirements here, and this constitutes the current Phase of the work.
Next steps would be to engage with selected homes of both residential and nursing home categories and varying sizes to test performance, with the aim to roll out within a twelve month period.  
The following developments would be to work with other innovation partners to integrate with others digital technology platforms to support care homes in managing their patients, it would also be further developed to enable roll out in assisted living, sheltered housing and residential properties.
What is the intellectual property status of your innovation?:
This product is in development, and this is the first time we have shared it as we are now at the point of needing further advice and assistance.  WMAHSN have been approached to support us on protecting the IPR for this innovation.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
3
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Read more
Hide details
Andrea Baker 02/02/2018 - 19:13 Sign Posted 3 comments
0
0
Votes

Innovation 'Elevator Pitch':
Simple visual tools that enable people who cannot communicate to convey the location and nature of their pain or discomfort. They can then be given appropriate support and treatment.
Overview of Innovation:
Many people suffering pain and discomfort cannot tell anyone about their distress. They may have a permanent or temporary communication difficulty, or they cannot speak English. Because of this, their pain and discomfort may be ignored.
 
Show Me Where is suite of simple visual tools that enable adults and children to convey the location and nature of their pain or discomfort. They can then be given appropriate support and treatment.
 
Show Me Where was created by Irene Hammond, a school nurse from the Hollies Special School, Cardiff for children with autism and speech disabilities. These children were unable to communicate pain and were impossible to examine because of anxiety or sensory issues. 
 
Since being introduced Show Me Where has been recognised as a valuable resource for a much wider range of people in a variety of settings including clinical, education and domestic.
 
Show Me Where is available in printed and digital app versions (via Apple and Google Play App Stores) for both children and adults. The apps also offer a range of languages to facilitate communication with non-English speakers. 
  • Arabic
  • Bengali
  • Polish
  • Somali
  • Urdu
  • Welsh
Show Me Where can be used with a wide range of people and in any setting:
  • Stroke   
  • Autism (ASD)
  • Dementia  
  • Disabilities e.g. CP, MS
  • Deafness and hearing problems
  • Intubated or tracheostomy
  • Trauma or anxiety
  • Non English-speakers
"We use Show Me Where as part of the Pain Assessment and Management Toolkit for Patients with Communication Difficulties in all clinical areas. We endorse its value in clinical practice." Sue Mogford, Lead Nurse, Pain Team, Cardiff and Vale UHB

The tools are very simple to use. Affected people are presented with a version of Show Me Where and asked if they are in pain. If ‘yes’ is indicated they are shown a list of body images to select from. Very quickly an accurate assessment can be made of the location and nature of pain and discomfort. Presenting the tool on a regular basis reduces stress and anxiety and ensures the early detection of pain with vulnerable people.
 
In a clinical environment it is helpful for family, friends and nursing assistants to triage individuals and therefore support a more rapid and effective examination by healthcare professionals. It also enables clinicians to inform the patient and gain consent for medical examination and interventions.

"This app is brilliant!" Sunshine Haskell BA Hons, PGCE Teacher, The Hollies Special School
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Many people suffering pain and discomfort are unable to tell anyone about their distress. They may have a permanent or temporary communication difficulty, or they cannot speak English. Because of this their pain and discomfort may be ignored. Show Me Where makes diagnosis and treatment more effective and efficient for health and social care professionals. It aslo improves the quality of life for individuals living with the pain and discomfort. Accessibility and parity are both improved.
Initial Review Rating
3.00 (2 ratings)
Benefit to WM population:
Many people suffering pain and discomfort are unable to tell anyone about their distress. They may have a permanent or temporary communication difficulty, or they cannot speak English. Because of this their pain and discomfort may be ignored. Show Me Where not only improves the detection, treatment and management of pain it makes diagnosis and treatment more effective and efficient.
Current and planned activity: 
Show Me Where has been available for some time via Cardiff and Vale University Health Board. They have entered a partnership with Focus Games Ltd to make the tools more widely available by promoting the tools more effectively. Show Me Where is officially endorsed by the following organisations
  • University Hospital of Wales (C&VUHB)
  • Llandough Hospital (C&VUHB)
  • St David's Children's Centre (C&VUHB)
  • Ty Hafan, Children's Hospice
  • Special Needs Schools in Wales
  • Welsh Ambulance Service Trust (WAST)
What is the intellectual property status of your innovation?:
IP is owned by Cardiff and Vale University Health Board
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
Being widely used in hospitals and special schools in Wales.
Measures:
Improve the recognition of pain and its management among people with communication difficultis. Especially vulnerable groups.
Adoption target:
Ideally every organisation or individual that deals with people who have communication difficulties would use Show Me Where. There is no minimum viability level.
Read more
Hide details
Andy Yeoman 29/01/2018 - 08:52 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Reduce bedblocking and improve ward care by enabling ward access to digital data upon admission of personal knowledge of the patient including This Is Me, My Passport and Risk data, and assist with stepdown process and therapy
Overview of Innovation:
ReMe supports dementia, older people, carers and families and accompanies the person across their care journey. ReMe was trialled and co-produced by dom care, care homes and in wards.
A new breed, we’ve christened ReMe ‘Activity Based’ software, to differentiate from care planning. For patient knowledge and the ability to enhance care comes from activities, not data input. By using algorithms to source bespoke internet images, music and videos and define a profile it’s possible to deliver more person-centred care. At ReMe’s core are activity tools that learn about the person, such as reminiscence and cognitive therapy, and enable discovering calming content for acute care strategies. ReMe stores life stories, preferences and interests and connects with a care circle, as well as creating automated activity reports which can be sent to the user's family.
Around this person-centred care core are business tools each care sector’s needs. Therefore, ReMe achieves an ROI by assisting in client acquisition, care assessment, acute care planning, management and paper reduction, activity creation, scheduling and data collation, whilst providing family and admin reporting. With cross care sector data connectivity and real portability, ReMe becomes part of a dementia acute care strategy.
For care in the community, ReMe’s free with premium subscriber services. With self-management, connectivity, entertainment and activities and by generating data, ReMe supports daily care, celebrates a life, strengthens family links and tackles agitation, depression and isolation, becoming a highly-personalised resource and recourse.
ReMe is used currently in the following care sectors.
For dom care, ReMe improves care, client engagement, reports and generates extra revenue through selling extra hours based on a wellbeing and family connected value added service.
For care homes, ReMe helps families engage in the care process, carers use tablets productively, reduces paper and enhances activities, therapy and reporting. ReMe improves care and saves money.
For hospitals, ReMe is a low-cost means to better know the patient; that improves admission, through digital connection to the care home and dom carer providing access to knowledge of the patients’ ‘day before’ care profile. ReMe enhances person centred care, patient wellbeing, reporting and stepdown.
ReMe is easily adopted with no legacy software or training needs.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
RemindMeCare (ReMe) delivers savings for the NHS through its care in the community self-management functionality reducing admissions, an improved admissions process (i.e. Digital This Is Me, Risk and My Health Passport), enhanced in-ward care, reduced medication and more informed step down.
 
ReMe provides connectivity with care homes, domiciliary care, day care centres and families, and enables better knowledge of the person to be used in person-centred care delivery.
 
Continuity of bespoke, tech advanced activities and therapies, that enhance patient wellbeing, engagement, person centred care and acute dementia care, generate improved patient outcomes, reduced agitation, medication and drugs costs, as well as better informed step down and earlier discharge.
 
Increased availability of personal and risk data reduces risk (and possibly litigation), resort to medication and wellbeing decline, so ReMe aims to reduce bed days.
 
ReMe supports improved family visits and overnight stays through the provision of familiar content and entertainment.
 
Automatic care activities recording, for CQC/admin reporting and research is available.
 
Evidence of value is shown only by the demand and positive feedback received from care homes, LA’s, hospitals and families nationwide but will be formalised shortly.
 
ReMe addresses the Next Steps NHS Five Year Forward View; by reducing A&E/GP visits, making patients information available to clinicians; enabling prescribing apps to help people manage their own health, addressing loneliness and aiding carer respite and assisting LA requirements regarding services provision and monitoring.
 
We’re pioneering this connected care approach in conjunction with SWLCC 5-year strategy, focussing on care quality, safety and cost savings, addressing the defined challenges of avoiding hospital admission, supporting ‘Community services to meet the highest standards and working more closely with primary care, mental health, acute hospital services and social care’. Our participation in the Better Care funded Croydon APA project defines ReMe’s role in the budget shift from hospitals to the integration of health and social care, through the coordination of care. Critically, ReMe addresses recommendations by NICE to focus on person centred and family care support through engaging consumers with a user-friendly product that promotes self-management of illness including long term conditions.
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
RemindMeCare delivers support for older people and people with dementia, their carers and families and which is portable and usable by their carers, from home to domiciliary, live-in, day care, residential and ward care. ReMe was developed with people in the NHS and trialled in wards and care homes.
ReMe is a new breed we’ve christened ‘Activity Based’ software to differentiate itself from care planning software. For knowledge of the person and the ability to enhance care is derived from activity provision, not from data input.
By providing self-management tools and engaging activities and by generating data, ReMe supports daily care, celebrates a life, strengthens links with family and tackles agitation, depression and isolation. ReMe becomes a daily highly personalised resource and recourse for those people involved in care.
ReMe’s suite of person-centred care algorithm based activity tools enhance care and are the constant core across all care sectors, and continually learn about the person wherever they may be. ReMe’s the only system that offers bespoke reminiscence and cognitive therapy by sourcing images, music and videos that are unique to the user and so enables discovering calming content for acute care strategies. ReMe stores life stories, preferences and interests with carers and a care circle, as well as creating automated activity reports which can be sent to the user's family.
Wrapped around this person-centred care core are business tools that address the needs of each care sector encountered by the person, including those common to all such as CQC reporting and family engagement.
RemindMeCare goes further, achieving an ROI for care businesses and wards by assisting in care assessment, acute care planning, management and paper reduction, activity creation/scheduling/planning and data collation, whilst providing family, admin and regulatory body reporting. With cross care sector data connectivity and real portability, ReMe becomes part of a dementia acute care strategy for whichever care sector at any time is caring for the person. For the ward, ReMe offers access to the vital knowledge of ‘the day before’ care profile of the admitted patient and the benefits that enhanced person centred care can deliver.
Usable on any platform and with encrypted data, ico compliance (G Cloud pending), ReMe has addressed information governance and digital security.
Please view videos (https://www.remindmecare.com/business/ward/ )
Current and planned activity: 
ReMeApp: self-management care tools that assist maintain care in the community, improve the ability of carers to deliver bespoke care and connect the person with their care circle and with their community; to reduce resort to GP and A&E through enhanced care circle engagement. Dementia care training is included and partnerships with Dementia Pathfinders and Worcester University will be extended achieve delivery.
ReMeData: Integration with Care Planning systems; ie with patient’s systems (such as CMC) and others as required.ReMeGP:  GP Connectivity. Through remote connectivity tools GP’s can remain engaged, be better informed but on a remote basis. The intended result is less resort to disturbing surgery visits. GP connectivity will be release in 2018.
ReMeComm: self-management care tools for those cared for in the community, that match the person cared for with local community activities (A partnership pending with Worcester University, CarersUK, MeetingDem and others. 
What is the intellectual property status of your innovation?:
We are the sole owners of our IP
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Simon Hooper 13/05/2017 - 21:13 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Coronary Artery Disease (CAD) is the leading cause of death world-wide. HeartFlow’s non-invasive technology, FFRct, has been found to accurately diagnose patients with suspected CAD, avoid unnecessary invasive procedures, and reduce healthcare costs
Overview of Innovation:
The diagnosis and care of patients with suspected coronary artery disease is significantly improved by the use of HeartFlow's FFRct analysis. Our process starts with data from a standard Coronary Computed Tomography Angiography (CCTA). High-quality (64 slice or greater) CT scanner images are sent to HeartFlow.

HeartFlow then creates a personalized, 3D model of each patient’s arteries. Where computational fluid dynamics are used to evaluate blood flow and assess the impact of blockages in the arteries. With this actionable information, clinicians can determine the right course of action for each patient.

While FFRct is still in an early  stage of adoption, there are now over 150 publications on the technology. Clinical trials have validated both the diagnostic accuracy and clinical utility. Most recently NICE issued guidance on HeartFlow FFRct, stating "The technology is non-invasive and safe, and has a high level for diagnostic accuracy... may avoid the need for invasive coronary angiography... Based on current evidence using HeartFlow can lead to cost savings of £214 per patient."

CT data is securely (Anonymised CCTA data) and seamlessly sent via our “HeartFlow Connect” once installation is approved by the hospital trust. HeartFlow ensures that the scans and FFRct results and analysis models are acceptable to a sites radiologists / radiographers.
 
Whilst this is an emerging diagnostic its well positioned to become an integral part of standard patient care for those who are at risk of CAD. As this is a new technique HeartFlow provides training to radiologists, radiographers, cardiologists and support staff. We work closely with each site to provide support and training to help evaluate the technology and as they begin to incorporate FFRct into their clinical practice. [A high level overview of HeartFlow’s training support can be found in the Adoption guide published by NICE. (see attached)]
 
HeartFlow FFRct users are invited to educational seminars and we are working on establishing a UK users group to help sharing best practice around FFRct’s use.
 
HeartFlow has received CE mark approval for use in UK/Europe.  CCTA image specifications for HeartFlow FFRct analysis; HeartFlow’s CCTA quality requirements are consistent with those of the Royal College of Radiology (RCR), British Society of Cardiovascular Imaging and the Society of Cardiovascular Computed Tomography (SCCT) performance of CCTA guidance document.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
The use of HeartFlow FFRct can improve patient care, efficiency, and lower medical costs:

Patient Care
  • HeartFlow FFRct provides a physician with both functional and anatomical data, improving diagnostic accuracy, thus reducing invasive procedures and associated complications
  • Improved diagnostic accuracy improves patient care and quality of life
  • Studies suggest that incorporating FFRct lowers patient radiation levels due to decreased angiography
Efficiency
  • Studies indicate that the application of FFRct may result in a reduction of unnecessary angiographies, improved cath lab efficiency, and reduced waiting lists
  • By providing both functional and anatomic data, physicians may be able to reduce the need for and waiting times associated with other diagnostic imaging tests
Cost of Care
  • As demonstrated in the NICE guidance, the use of HeartFlow FFRct can potentially reduce the cost of care. NICE estimates an average savings of £214 per patient. This saving is based on not conducting inappropriate invasive diagnostics.
  • A Japanese study has indicated that the use of the CCTA-FFRct strategy to select patients for Percutaneous Coronary Intervention (PCI) would result in 32 % lower costs and 19 % fewer cardiac events in 1 year compared to the most commonly used CAG-visual strategies. 
 
“The HeartFlow FFRct Analysis provides a definitive understanding of both anatomical and functional findings, without any additional testing or risk for patients. Application of the HeartFlow FFRct Analysis is likely to transform the quality of care we can provide for patients, ensuring the most accurate diagnosis and the best treatment plan, as well reducing the need for invasive coronary angiography – a procedure not without its risks.”
  -  Dr. Joseph Mills, Liverpoool Heart and Chest Hospital
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
As stated in the NICE guidance, the adoption of HeartFlow FFRct in the West Midlands region could improve patient care and outcomes while generating significant savings for the region.
 
We are looking for additional adoption sites and would be interested in hearing from West Midlands Trusts that would like to take the lead in establishing our UK user group.  
Current and planned activity: 
HeartFlow is in early conversations with NHS Trusts and commissioners. A handful of early adopting NHS medical centres have begun to provide HeartFlow FFRct for their patients. HeartFlow is engaging with interested physicians at centres with high quality CT capabilities.

UK Sites where Heartflow FFRct is being used:
  • St. Bartholomew’s Hospital (London)
  • Liverpool Heart and Chest
  • Russell Hall Hospital (Dudley, West Midlands)
  • Freeman Hospital (Newcastle)
HeartFlow is in discussion with other UK site about adoption of FFRct.

Planned / required activity
  • We are looking for additional adoption sites and would be interested in hearing from Trusts that would like to take the lead in establishing our UK user group 
  • Whilst we have undertaken worldwide studies we are always interested in ongoing evaluation / validation and collaborative developments technically and with clinical pathway integration.
  • In the future we plan on conducting clinical trials based & focused on specifically the UK population.
What is the intellectual property status of your innovation?:
HeartFlow has established significant intellectual property and has been issued several patents.
HeartFlow received CE IIA mark approval for use in UK/Europe in July 2011. The technology is also ISO 13485 certified.  

Return on Investment
Savings have been demonstrated in clinical trials (PLATFORM), third party health economic modelling (NICE guidance, Int’l Journal of Cariology 183 (2015) 173-7), and real world experience at early adopting centres.
 
NICE recommendations for Heartflow FFRct (February 2017) state:  “Using HeartFlow FFRct may lead to cost savings of £214 per patient. By adopting this technology the NHS in England may save a minimum of £9.1 million (annually) by 2022 by avoiding invasive investigation and treatment.  
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Regional Scalability:
Liverpool Heart and Chest has performed more HeartFlow analyses than any other site. They have demonstrated clinical and economic benefits to incorporating HeartFlow FFRct into their practice. The uptake is due in part to to the strong support from their regional CCG.
Measures:
HeartFlow is seeking to achieve the following outcomes:
 - Improved patient care: Reduction in unnecessary invasive angiographies and eventually a reduction in waiting times for those patients that need angiographies
 - Reduction in Healthcare Costs: NICE estimates cost savings of 214 GBP per patient. We are working with existing sites to demonstrate real world outcomes.
 - Quality of Life: HeartFlow's clinical utility trial, PLATFORM, demonstrated an improvement in quality of life when FFRct was incorporated into patient care pathways. It is likely that this is in part due to the avoidance of unnecessary interventions. To date we have not seen any adverse events from avoiding invasive procedures.   
Adoption target:
NICE estimates cost savings of 9.1M GBP annually within five years. To reach this objective approximately 35,000 patients would need to have access to a HeartFlow FFRct analysis. 
Read more
Hide details
Ben Forrest 12/05/2017 - 17:12 Detailed Submission 3 comments
5.7
3
Votes
-99999
Innovation 'Elevator Pitch':
Airglove is a patient warming system that gently heats the arm, raising fragile or hidden veins, making them easier and less painful to access.
 
“Up to 35% of patients require heated cannulisation due to fragile or hidden veins”
 
Overview of Innovation:
Airglove is a unique warming system developed to enable access to the veins in a patients arm for the delivery of intravenous drugs. It gently heats the patients arm up as it forces warm air through a single use double walled polythene glove.


www.greencrossmedico.com/products/airglove

Patient Solution
Airglove warming system works in just 3 minutes gently heating the patients arm to the selected temperature. Its so easy to use the nurse/practitioner simply selects the chosen temperature setting according to the patients skin type, places the patents arm in the double walled polythene glove and selects start. The patient will feel the warm air fill the glove up and vent away through a single slit perforation and after 3 minutes the machine will automatically stop with an alert sound.

Patient Clinical Considerations
With extended courses of treatment such as chemotherapy repeated cannulation is often required. Airglove can benefit fragile or hidden veins by warming the local area which gently raises the veins allowing for the insertion of the cannula. This reduces the time taken, costs and the number of attempts required which is more comfortable for both the patient and nurse/practitioner.

Patient Comfort
In addition to the benefits of easier cannulisation Airglove can help to make the patient more comfortable and relaxed with its gentle warming system with the confidence that the nurse practitioner will be able to access their veins.

Temperature Settings
The temperature can be selected to suit each skin type sensitive 31.5C, normal 35.5C or slightly heavier 38.5C with the Airglove automatically re-setting itself to normal skin type (setting 2: 35.5C) after each use. After 3 minutes the Airglove unit automatically switches off with an alert sound.

Patient Safety
No more improvisation with warm water, heat packs or even heated towels to try and gain access to patients veins which can be a Health & Safety issue.

Approved Medical Device
Airglove has taken 5 years of development, research, testing and trials by Green Cross Medico in conjunction with NHS Innovations South East and The Maidstone and Tunbridge Wells NHS Trust hospital. It was developed as there was a clearly defined and acknowledged need by medical professionals at The Maidstone and Tunbridge Wells NHS Trust hospital oncology department. Further trials will be starting shortly with Beatson West of Scotland Cancer Centre, Glasgow.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Patient and medicines safety / Person centred care
Benefit to NHS:
Airglove was initially developed for chemotherapy patients who have hidden or fragile veins and especially in patients who are in their 5th or 6th cycle of therapy.

The use of Airglove affords easier cannulation with fewer attempts being required (sometimes up to 6 attempts by 3 different staff can be attempted to access a difficult vein). This improved ease of access not only makes the patient’s experience far less traumatic, but ensures a better clinical outcome and saving valuable nursing/practitioner time and consumables.

Data regarding patient experience and resource savings. Patient evaluation trials at Maidstone and Tunbridge Wells Hospital NHS Trust showed 87.5% success in cannulation on first attempt with the most difficult to cannulate patients. With cannulation success, the potential cost savings on consumables are up to £50k per oncology unit, plus the nursing/practitioner’s time. Airglove is now available and is in use or on trial in over 10 hospital trusts with more waiting for demonstrations.

Improved hygiene and reduced risk of cross infection will result from the use of Airglove vs currently used methods of locally heating the arm e.g. hot towels or buckets of warm water. Only Airglove’s single use only, double walled polythene sleeve comes into direct contact with the patient’s skin. Heated air is circulated between the double wall of the sleeve and is not directly blown across the skin and so the risk of cross contamination is reduced.

Airglove can also be used for other interventions where venous access proves difficult due to fragile or difficult to find veins e.g. routine phlebotomy.

Airglove has been developed in partnership with NHS Innovations South East and The Maidstone and Tunbridge Wells NHS Trust Hospital (MTW). It has undergone testing by the Electronics and Medical Engineering (EME) trials for temperature control and stability, and on a cohort of healthy volunteers. The Maidstone & Tunbridge Wells NHS Trust has completed the patient evaluation trials with the oncology department. They achieved 87.5% 1st time success with their hardest to cannulate patients (MTW report available).






 
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
The West Midlands patients and healthcare system would equally share the benefits described above for the NHS in general.

There are 13 NHS Trusts within the West Midlands having oncology departments.
 
Current and planned activity: 
Airglove is now available in the UK.

If you would like to trial Airglove for 4 weeks contact Sheena Jack 07944 519796 or email: sheena.jack@greencrossmedico.com

Airglove has been developed in partnership with NHS Innovations South East and The Maidstone and Tunbridge Wells NHS Trust Hospital (MTW). It has undergone testing by the Electronics and Medical Engineering (EME) trials for temperature control and stability, and on a cohort of healthy volunteers. The Maidstone & Tunbridge Wells NHS Trust has completed the patient evaluation trials with the oncology department. They achieved 87.5% 1st time success with their hardest to cannulate patients (MTW report available).




We are also working on a further evaluation with the Beatson West of Scotland Cancer Centre, Glasgow, along with NICE Medical Technologies Evaluation Programme.


 
What is the intellectual property status of your innovation?:
Airglove is a registered Trademark.

Airglove is Patented Internationally.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Regional Scalability:
We have not implemented in scale in any other region yet, as the product will not be available commercially until June 2018. From this point on it will be available to purchase across the West Midlands region directly from Green Cross Medico until available through NHS supply Chain.
Measures:
The success of the innovation will be measured by the uptake of Airglove throughout all 160+ oncology units throughout the UK.

This will also be determined by the cost savings to the NHS, along with patient comfort and safety, which will be assessed from the success of the patient evaluation and clinical trials.

Adoption target:
If Airglove is adopted by the 13 NHS Trusts in the WM region into their respective 14 oncology units, supplying 3 Airglove units per oncology unit, this represents 42 Airglove units using 127,400 gloves per annum.

This could generate potential savings of £369,460 per annum to the Regional NHS.

Our trials and experience to date has demonstrated that the use of the Airglove system improves the efficiency of the nurse/practitioner, coupled to the direct consumable cost savings mentioned previously....in addition to the patient comfort benefits.

We can see from the Maidstone & Tunbridge Wells service evaluation how much of a difference it makes to the patients comfort and safety when they can be cannulated successfully on the first attempt, and to take this to the next level where all patients not just oncology can get the benefit as there are a lot of 'old and cold' as we say that are hard to cannulate and are dehydrated too.
Adoption target:
If Airglove is adopted by the 13 NHS Trusts in the WM region into their respective 14 oncology units, supplying 3 Airglove units per oncology unit, this represents 42 Airglove units using 127,400 gloves per annum. 

This could generate potential savings of £369,460 per annum to the Regional NHS.
Read more
Hide details
Sheena Jack 10/04/2017 - 14:29 Detailed Submission 1 comment
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Radar supports health and social care organisations in holistically managing all aspects of their quality and compliance activity, whether intuitively building a CQC evidence portfolio or managing audit, incidents and risk.
Overview of Innovation:
Radar Healthcare system has been developed using the latest technologies and platforms to ensure a cutting edge and sustainable solution. The system adopts proven business rules in use across the health & social care sector in the UK and incorporates the Care Quality Commission (CQC) guidelines and procedures.
 
Radar Healthcare from Smartgate Solutions has been developed in partnership with knowledgeable and respected healthcare professionals. The system is scalable and configurable to organisational needs to meet both internal and regulatory requirements.

The Radar Healthcare modules help care providers meet their daily operational challenges and associated quality and compliance requirements. 
 
Radar supports organisations by: Taking the worry out of quality & compliance
  • A responsive system, allowing you to visualise and manage risk, training and regulatory compliance across the business domain.
Gain a clear line of sight into performance
  • Intuitive and dynamic dashboards providing real-time visibility of business performance at both location and organisational levels.


Automation of key procedures for operational efficiency
  • Translating business rules and SOP’s into action through our automated workflows and action tracking.
Reduce costs
  • Supporting a systems approach delivering demonstrable ROI across business resources, time and staffing.
 Radar Healthcare is currently in use across multiple service areas including Social Care, Primary Care, Specialist Clinics, Acute Care  and Patient Transport.
 
It’s primary purpose is to assist in ensuring each organisation meets relevant regulatory compliance standards and support organisations reduce duplication and effort in managing that process.
 
It will allow existing processes and procedures to be followed more efficiently and enable the introduction of new processes and procedures that are currently unfeasible with existing systems.
 
Key Facts
  • The system is made up of specific modules, each providing a range of functions that can support organisations in their daily operational activity.
  • All Modules work collaboratively and share data to avoid duplication.
  • Data can be integrated from various sources and other software system.
  • Dashboards and reports can be viewed and created by employees, by department, by directorate or as an entire organisation.
  • Each module has the ability to accommodate pre-configured workflows aligned to your existing SOPs, policies and procedures.
 www.smartgatesolutions.co.uk
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Education, training and future workforce / Wealth creation / Digital health
Benefit to NHS:
Radar Healthcare modules have been developed to help care providers meet their daily operational challenges and associated regulatory requirements. 
 
Adopting proven tool kits and processes, Radar Healthcare ensures compliance with the essential standards relating to the quality and safety of care as defined within the CQC and other regulatory bodies.
 
Cost Improvement (CIP) Opportunities
The CIP opportunities are variable and based upon the modules selected. Efficiency savings are realised through two specific means:
  1. Replacement of existing systems in use across the organisation
  2. Redeployment of posts supporting quality and compliance management and re-deploying skills to vacancies within the organisation
 
A high level simulation exercise exploring how the implementation of Radar could support the reduction of cost within an NHS Hospital in the North of England (approximately 3,500 staff serving a population of c250,000 people) identified potential savings of over £300,000 over a 3 year period.
 
Smartgate Solutions have developed a cost calculator capable of identifying cost against current systems and workforce requirements.
 
Efficiency Savings
Additional efficiency improvements can be realised through:
  • Ensuring compliance with CQUIN targets or other commissioning KPIs
  • Improved efficiency and productivity in managing quality and compliance activity
  • Smartgate can support organisations with their recruitment processes and reduce the time spent undertaking training post employment. Radar allows you to issue training and development content to employees prior to their engagement and for completion online, effectively tracking and monitoring their progress against the training content.
  • Reducing the time spend responding to requests from regulatory bodies and building evidence portfolios. Radar supports the on-going development of evidence portfolios, providing clear audit trails and concise reporting.
  • The system intuitively allows users and organisations to share information, allocate tasks and distribute vital information in real time. It provides a safe and effective way of sharing learning and information.
 Client Testimonial
“We are committed to delivering the highest levels of service and CQC compliance. Radar Healthcare has been the key factor in achieving and exceeding these goals.“
John Butterfield, CEO, ER Systems
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Radar supports providers and commissioners of health and care services to effectively manage and monitor their quality and compliance expectations, deliverables and regulatory requirements with greater efficiency and often with greater effectiveness.
 
Radar enables organisations to re-deploy their scarce resources to focus on the delivery of care, freeing clinical expertise from administrative activities. 
Current and planned activity: 
Current NHS Activity:
Radar is currently utilised by numerous providers of health and care services, many of which provide NHS services.
 
We are currently engaged in discussions with both CCGs and NHS Foundation Trusts.
 
At present we are exploring opportunities to grow our engagement with NHS organisations and are seeking support and guidance from colleagues at WMAHSN, Medilink WM and the wider regional health and social care communities.

Planned/required activity:
  • Procurement / Adoption of: -  Growth and increased adoption of Radar across NHS provider and commissioner organisations  
  • Partnership: We are interested in exploring partnership opportunities with NHS organisations that may help to realise a financial ROI
What is the intellectual property status of your innovation?:
All product IP is wholly owned by Smartgate Solutions Ltd
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
2
Read more
Hide details
Tom Lindley 30/03/2017 - 10:44 Publish Login or Register to post comments
0
0
Votes
-99999

Active Campaigns